December 12, 2024 13:19 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Devendra Fadnavis meets PM Modi amid suspense over Maharashtra portfolio allocation | Congress wants to deviate the issue of Sonia Gandhi-George Soros link: JP Nadda | Bengaluru techie suicide: Atul Subhash's family demanded Rs. 10 lakh as dowry leading to my father's death, claims estranged wife | Syria rebels torch tomb of ousted president Bashar al-Assad's father | Donald Trump vows to eliminate birthright citizenship after taking charge | No alliance with Congress in Delhi polls: AAP chief Arvind Kejriwal | Bengaluru techie's suicide: Atul Subhash's wife and her family booked | Bengaluru techie's suicide: Atul Subhash's wife and her family booked | INDIA bloc to knock on Supreme Court's doors over alleged EVM manipulation during Maharashtra polls | 'Babri Masjid should be rebuilt in Bengal's Murshidabad': TMC MLA Humayun Kabir sparks row
Mankind
Image credit: Facebook/Mankind Pharma

Mankind Pharma acquires Bharat Serums and Vaccines from Advent International for Rs 13,630 crore

| @indiablooms | Jul 26, 2024, at 07:20 pm

Mumbai/IBNS: Mankind Pharma Ltd, India’s fourth largest pharmaceutical company by market share, on Thursday (July 25) said it has entered into a definitive agreement to acquire a 100 percent stake in Bharat Serums and Vaccines (BSV) from Advent International for an enterprise value of Rs 13,630 crore, according to reports.

BSV, a branded specialty pharma platform in women’s health and critical care, reported revenues of Rs 1,723 crore in FY24, delivering robust 20 percent year-on-year growth with adjusted EBITDA margins of 28 percent.

The business has grown at a 21 percent revenue compound annual growth rate over the last three years, reports Business Standard.

According to reports, over 2,500 employees of BSV will be joining Mankind Pharma Ltd.

Earlier in February 2020, American global private equity firm Advent International Corporation acquired a 74 percent stake in BSV, providing a complete exit to private equity investors OrbiMed Asia and Kotak PE and a partial exit to the promoter Daftary family, as per reports.

Advent International, following approval from the Department of Pharmaceuticals (DoP), acquired the remaining 26 percent stake from the Daftary family in 2023-24.

The Business Standard reported, quoting Shweta Jalan, managing partner and head of Advent India, that Mankind Pharma’s investment in BSV is a testament to their approach of identifying and nurturing unique businesses, working with high-quality management teams and building these businesses into respected industry leaders.

The FY24 sales of Mankind Pharma Ltd. stood at Rs 10,335 crore, with Ebitda at Rs 2,550 crore translating into Ebitda margins of 24.7 percent.

According to a report by Mint, the acquisition of BSV will mean expansion of Mankind Pharma's brand portfolio that will now contain more than 40 brands valued at more than Rs 50 crore.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.